Back

HECTD3 attenuates cardiac hypertrophy acting as an E3 ligase of SUMO2

27 August 2018 (09:30 - 09:45)
Organised by:
Congress Presentation Part of: Heart Failure: new targets for treatment Cardiac Hypertrophy ESC Premium Access ESC Congress 2018

About the speaker

Photo
Doctor Ashraf Rangrez

University Medical Center of Schleswig-Holstein, Kiel (Germany)

5 More presentations in this session

Presentation thumbnail
Angiotensin II-dependent activation of NADPH oxidase 4 contributes to muscle wasting in mice via downregulation of NF-E2-related factor 2
Doctor T. Kadoguchi (Tokyo, JP)
Abstract Slides Video
Presentation thumbnail
Excessive mitochondrial reactive oxygen species emission from circulating blood cells is associated with severity of heart failure and exercise intolerance
Doctor R. Shirakawa (Sapporo, JP)
Abstract Slides Video
Presentation thumbnail
Positive cardiac inotropy by carvedilol via unique beta-arrestin2-dependent SERCA2a stimulation
Associate Professor A. Lymperopoulos (Fort Lauderdale, US)
Abstract Slides Video
Presentation thumbnail
Empagliflozin potently reduces sarcoplasmic Ca leak and increases Ca transient amplitude of human failing ventricular cardiomyocytes
Mr J. Mustroph (Regensburg, DE)
Abstract Slides Video
Presentation thumbnail
RNA methylation in cardiac hypertrophy and heart failure
Mr E. Buchholz (Goettingen, DE)
Abstract

Access the full session

Session thumbnail
Heart Failure: new targets for treatment

The Event

Event poster

ESC Congress 2018

27 August 2018 09:30 CET
You may be interested in
thumbnail
Webinar
Elevating cardiac expertise: practical approach to left ventricular hypertrophy phenotypes assessment
thumbnail
Congress Session
Cardiac MRI and the evaluation of hypertrophy: modern insights
thumbnail
Congress Presentation
Left ventricular hypertrophy and sudden cardiac death

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources